327 related articles for article (PubMed ID: 28755839)
1. Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy.
Crane A; Brubaker WD; Johansson JU; Trigunaite A; Ceballos J; Bradt B; Glavis-Bloom C; Wallace TL; Tenner AJ; Rogers J
Alzheimers Dement; 2018 Feb; 14(2):243-252. PubMed ID: 28755839
[TBL] [Abstract][Full Text] [Related]
2. Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.
Brubaker WD; Crane A; Johansson JU; Yen K; Garfinkel K; Mastroeni D; Asok P; Bradt B; Sabbagh M; Wallace TL; Glavis-Bloom C; Tenner AJ; Rogers J
Alzheimers Dement; 2017 Dec; 13(12):1397-1409. PubMed ID: 28475854
[TBL] [Abstract][Full Text] [Related]
3. A novel role for SHARPIN in amyloid-β phagocytosis and inflammation by peripheral blood-derived macrophages in Alzheimer's disease.
Krishnan D; Menon RN; Mathuranath PS; Gopala S
Neurobiol Aging; 2020 Sep; 93():131-141. PubMed ID: 32165044
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q.
Webster SD; Galvan MD; Ferran E; Garzon-Rodriguez W; Glabe CG; Tenner AJ
J Immunol; 2001 Jun; 166(12):7496-503. PubMed ID: 11390503
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
[TBL] [Abstract][Full Text] [Related]
6. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
Nitsch RM; Hock C
Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
[TBL] [Abstract][Full Text] [Related]
7. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated immunotherapy for Alzheimer's disease.
Solomon B
Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
[TBL] [Abstract][Full Text] [Related]
9. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
[TBL] [Abstract][Full Text] [Related]
10. Modified immunotherapies against Alzheimer's disease: toward safer and effective amyloid clearance.
Wang YJ; Zhou HD; Zhou XF
J Alzheimers Dis; 2010; 21(4):1065-75. PubMed ID: 21504118
[TBL] [Abstract][Full Text] [Related]
11. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
Delrieu J; Ousset PJ; Caillaud C; Vellas B
J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
[TBL] [Abstract][Full Text] [Related]
12. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
13. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
Murakami K
Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
[TBL] [Abstract][Full Text] [Related]
14. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
15. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain.
Morgan D
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):7-15. PubMed ID: 19275633
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives].
Karkos J
Fortschr Neurol Psychiatr; 2004 Apr; 72(4):204-19. PubMed ID: 15095177
[TBL] [Abstract][Full Text] [Related]
17. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
Solomon B
Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
[TBL] [Abstract][Full Text] [Related]
19. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
[TBL] [Abstract][Full Text] [Related]
20. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
